Several other research analysts also recently commented on the company. Credit Suisse Group reiterated an “outperform” rating on shares of Siemens Healthineers in a research note on Tuesday, November 10th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Siemens Healthineers in a research note on Tuesday, October 6th. AlphaValue upgraded Siemens Healthineers to a “reduce” rating in a research note on Wednesday, December 9th. Bank of America upgraded Siemens Healthineers from a “neutral” rating to a “buy” rating in a research note on Thursday, December 3rd. Finally, Commerzbank AG (CBK.F) upgraded Siemens Healthineers from a “hold” rating to a “buy” rating in a research note on Thursday, December 3rd. Two analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. Siemens Healthineers presently has an average rating of “Hold”.
OTCMKTS:SMMNY opened at $26.67 on Tuesday. Siemens Healthineers has a twelve month low of $16.19 and a twelve month high of $27.34. The stock’s 50 day moving average price is $25.12 and its two-hundred day moving average price is $23.61.
Siemens Healthineers Company Profile
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company operates through three segments; Imaging, Diagnostics, and Advanced Therapies. The Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems.
Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.